Sign in below to access your subscription for full content You will be directed to acponline.org to register and create your Annals account
The Committee will discuss new drug application (NDA) 215244, for elamipretide hydrochloride injection, submitted by Stealth BioTherapeutics Inc., for the tr…
BackgroundAficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacoki…
∗Address for correspondence: Dr Nosheen Reza, Perelman School of Medicine, 3400 Civic Center Boulevard, 11th Floor South Pavilion, Philadelphia, Pennsylvania 19104, USA. E-mail: E-mail Address:…
AbstractBackgroundHypertrophic cardiomyopathy (HCM) is a common inherited cardiac disease, and clinical and genetic family screening is recommended by guidelines.ObjectivesThis study sought to inve…
∗Address for correspondence: Dr Michelle M. Kittleson, Department of Cardiology, Smidt-Heart Institute, Cedars-Sinai Medical Center, 8670 Wilshire Boulevard, 2nd Floor, Los Angeles, California 90211, USA.…
AbstractBackgroundObstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associat…
Read it now on PracticeUpdate.com
EP Lab Digest speaks with Ahmad Masri, MD, MS, about contemporary management of hypertrophic cardiomyopathy, including recent advances, pharmacologic treatment options, new guidelines, and future…
The Knight Cardiovascular Institute Research Project Coordinator acts as a key staff member to our Cardiology Clinical Trials program. They are assigned a focused area…
This cross-sectional study describes national and regional Medicare spending and out-of-pocket costs for tafamidis from its approval in 2019 to 2021.
